Products for Research Use Only
RegisterLogin

Briquilimab

CAT: 0804-HY-P99488-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99488-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit) . Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema[1][2].
CAS Number
2574591-89-0
Product Name Alternative
JSP-191; AMG-191
UNSPSC
12352203
Target
C-Kit
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/briquilimab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Briquilimab]
Molecular Weight
(145.61 kDa)
References & Citations
[1]Rajni Agarwal, et al., First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency, Blood, Volume 136, Supplement 1, 2020, Page 10, ISSN 0006-4971.|[2]Dawoon Jung, et al., Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia, Transplantation and Cellular Therapy, Volume 30, Issue 9, 2024, Pages 923.e1-923.e9, ISSN 2666-6367|[3]Pang, W. W., et al., (2019) . Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood, 133 (19), 2069–2078. |[4]Kwon, H. S., et al., (2019) . Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood, 133 (19), 2104–2108.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Alternative Products

CatalogName
T78305-01Briquilimab
GTR18398935-01Briquilimab Antibody
MBS1563492-01Research Grade Briquilimab
E55B0877Briquilimab (Reference antibody)
ICH5415-10mgBriquilimab Biosimilar - Research Grade
GTR18697237-01Briquilimab Human Monoclonal Antibody
GTR18780450-01(Briquilimab) Biosimilar Reference Antibody
A135601Briquilimab Biosimilar (Monoclonal, IgG1-kappa)
RA0444-01Briquilimab (Biosimilar Reference Antibody) (KIT)
PX-TA1820-01Briquilimab Biosimilar - Anti-KIT mAb - Research Grade

Popular Products